glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results LANDMARK ALERT 🚨 REPRIEVE Trial results: Pitavastatin provides over 35% reduction in MACE in patients with HIV! Real-World Evidence for GLP-1 Receptor

As of January 2026, states with some Medicaid coverage include: Massachusetts (Zepbound preferred for adults), Minnesota, Mississippi, New York, North Carolina (reinstated Dec 2025), and Wisconsin

Lilly will need to compile the complete clinical data package, which takes several months after the last trial reports

Batch-linked COA access, Janoshik source-lab documentation, Testide verification, and LAL screening for supported batches

It performs three basic functions: Reduces appetite by signalling satiety to the brain and suppressing cravings Slows down digestion and delays gastric emptying to make you feel fuller for longer Stimulates insulin secretion and suppresses glucagon release Collectively, this helps with blood sugar control and maintaining a healthy weight

It appears to work synergistically with GLP-1 to produce greater weight reduction than either receptor agonist alone

thus concomitant administration of atorvastatin with these drugs can lead to increased metabolism of atorvastatin and reductions in the plasma concentrations of atorvastatin